Response to interferon of GB virus C and hepatitis C virus in patients with chronic hepatitis

Am J Gastroenterol. 1997 Nov;92(11):1981-5.

Abstract

Objectives: To evaluate the response to interferon and capacity to induce liver disease of a putative non-A to E hepatitis virus designated GB virus C (GBV-C).

Methods: RNA of GBV-C was detected by reverse transcription polymerase chain reaction with nested primers deduced from the 5'-noncoding region. It was titrated, along with RNA of hepatitis C virus (HCV), in 16 co-infected patients (11%) out of 140 patients who received interferon.

Results: At the completion of a 6-month course of interferon (total dose: 516-774 million units), GBV-C RNA disappeared from serum in seven (44%) and HCV RNA from serum in 11 (69%) patients. At 6 months after interferon treatment ended, GBV-C RNA remained cleared in three patients (19%), and HCV RNA was persistently undetectable in four (25%). One patient lost both GBV-C and HCV RNAs. The three patients whose serum was cleared of GBV-C RNA had pretreatment titers of the virus (two with 10[1]/ml and one with 10[2]/ml) that were considerably lower than the titers of 13 patients (one with 10[2]/ml, eight with 10[3]/ml, and four with > or = 10[4]/ml) without such clearance. The decrease in alanine aminotransferase levels paralleled the response of HCV RNA but not that of GBV-C RNA to interferon. The response of HCV at 6 months after interferon in the co-infected patients (4/16 or 25%) did not differ significantly from that in patients without GBV-C infection (44/124 or 35%).

Conclusions: The sensitivity of GBV-C to interferon is comparable to but independent of HCV. Co-infection with GBV-C does not influence the response to interferon of patients with chronic hepatitis C.

Publication types

  • Comparative Study

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Biomarkers / blood
  • Drug Evaluation
  • Female
  • Flaviviridae* / genetics
  • Genotype
  • HIV Antibodies / blood
  • Hepacivirus / genetics
  • Hepatitis B Antibodies / blood
  • Hepatitis C Antibodies / blood
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / immunology
  • Hepatitis C, Chronic / therapy*
  • Hepatitis, Viral, Human / blood
  • Hepatitis, Viral, Human / immunology
  • Hepatitis, Viral, Human / therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Male
  • RNA, Viral / blood
  • Recombinant Proteins
  • Retrospective Studies
  • Time Factors

Substances

  • Antiviral Agents
  • Biomarkers
  • HIV Antibodies
  • Hepatitis B Antibodies
  • Hepatitis C Antibodies
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins